DelveInsight’s “Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Campylobacter Infections, historical and forecasted epidemiology as well as the Campylobacter Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Campylobacter Infections market report provides current treatment practices, emerging drugs, Campylobacter Infections market share of the individual therapies, and current and forecasted Campylobacter Infections market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Campylobacter Infections treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Campylobacter Infections market.
Some of the key facts of the Campylobacter Infections Market Report:
-
Campylobacter is 1 of 4 key global causes of diarrhoeal diseases. It is considered to be the most common bacterial cause of human gastroenteritis in the world.
-
Campylobacter infections are generally mild but can be fatal among very young children, the elderly, and immunosuppressed individuals.
-
The burden of foodborne diseases, including Campylobacteriosis, is substantial: every year almost 1 in 10 people fall ill and 33 million of healthy life years are lost. Foodborne diseases can be severe, especially for young children. Diarrhoeal diseases are the most common illnesses resulting from unsafe food, with 550 million people falling ill yearly (including 220 million children under the age of 5 years). Campylobacter is 1 of the 4 key global causes of diarrhoeal diseases.
-
Researchers don’t have exact numbers of how many people have it each year. That’s because most people don’t go to the doctor for food poisoning, such as Campylobacter infections. Healthcare providers diagnose Campylobacteriosis in about 20 out of every 100,000 people yearly. However, some estimates put the number of Campylobacter infections at more than 1.5 million every year. This is one of the most common foodborne illnesses in the U.S.
Key benefits of the report:
-
The report covers the descriptive overview of Campylobacter Infections, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
-
Comprehensive insight has been provided into the Campylobacter Infections epidemiology and treatment in the 7MM
-
Additionally, an all-inclusive account of both the current and emerging therapies for Campylobacter Infections is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
-
A detailed review of the Campylobacter Infections market; historical and forecasted is included in the report, covering drug outreach in the 7MM
-
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Campylobacter Infections market
Got queries? Click here to learn more about Campylobacter Infections Market Insights
Campylobacter Infections Overview
Campylobacter infection is a common foodborne illness. You usually get it from eating contaminated food, especially raw or undercooked poultry. You can also get it from drinking contaminated water or raw milk, or handling infected animal feces.
Diagnosis, particularly to differentiate Campylobacter infection from ulcerative colitis, requires microbiologic evaluation. A stool culture should be obtained plus blood cultures for patients with signs of focal infection or serious systemic illness. White blood cells are present in stained smears of stool. Rapid molecular and antigen assay stool tests are also available. Most enteric infections caused by C. jejuni resolve spontaneously; if they do not, azithromycin 500 mg orally once a day for 3 days may be helpful. Because resistance to ciprofloxacin is increasing, this drug should be used only when susceptibility has been established, but even then resistance has been reported to emerge with fluoroquinolone therapy. For patients with extraintestinal Campylobacter infections, antibiotics (eg, imipenem, gentamicin, ampicillin, a 3rd-generation cephalosporin, erythromycin) should be given for 2 to 4 weeks to prevent relapses.
Campylobacter Infections Epidemiological Insights
-
A total of 1892 children had 7601 diarrheal and 26 267 nondiarrheal stool samples tested for Campylobacter. We describe a high prevalence of infection, with most children (n = 1606; 84.9%) having a Campylobacter-positive stool sample by 1 year of age.
-
Factors associated with a reduced risk of Campylobacter detection included exclusive breastfeeding (risk ratio, 0.57; 95% confidence interval, .47–.67), treatment of drinking water (0.76; 0.70–0.83), access to an improved latrine (0.89; 0.82–0.97), and recent macrolide antibiotic use (0.68; 0.63–0.74).
-
A high Campylobacter burden was associated with a lower length-for-age Z score at 24 months (−1.82; 95% confidence interval, −1.94 to −1.70) compared with a low burden (−1.49; −1.60 to −1.38). This association was robust to confounders and consistent across sites.
-
Campylobacter infection was also associated with increased intestinal permeability and intestinal and systemic inflammation.
Campylobacter Infections Epidemiological Segmentation
-
Total Campylobacter Infections diagnosed cases
-
Total Campylobacter Infections age-specific diagnosed specific cases
-
Total Campylobacter Infections treated cases
Campylobacter Infections Market Outlook
The Campylobacter Infections market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Campylobacter Infections market trends by analyzing the impact of current Campylobacter Infections therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Campylobacter Infections market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Campylobacter Infections market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Campylobacter Infections market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Campylobacter Infections Market Landscape
Campylobacter Infections Key Companies
-
Lumen Bioscience
-
And others
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary of Campylobacter Infections
-
Disease Background and Overview
-
Epidemiology and patient population
-
Campylobacter Infections Emerging Therapies
-
Campylobacter Infections Market Outlook
-
Market Access and Reimbursement of Therapies
-
Appendix
-
Campylobacter Infections Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
-
About DelveInsight
Click here to read more aboutCampylobacter Infections Market Insights
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com